Generic Name and Formulations:
C1 esterase inhibitor (human) 500 Units/vial; lyophilized pwd for IV infusion after reconstitution; preservative-free.
Shire US, Inc.
Indications for CINRYZE:
Routine prophylaxis against angioedema attacks in patients ≥6yrs with hereditary angioedema (HAE).
Give by IV infusion at a rate of 1mL/min (10mins). ≥12yrs: 1000 Units every 3–4 days. May consider doses up to 2500 Units (max 100 Units/kg) every 3–4 days if inadequate response.
<6yrs: not established. Give by IV infusion at a rate of 1mL/min (5mins). 6–11yrs: 500 Units every 3–4 days. May adjust dose up to 1000 Units every 3–4 days based on response.
Contains human plasma; monitor for possible infection transmission (eg, viruses, Creutzfeldt-Jakob disease agent). Have epinephrine available to treat hypersensitivity reactions. Monitor patients with known risk factors for thrombotic events. Pregnancy. Nursing mothers.
Headache, nausea, rash, vomiting, fever; thrombotic events, hypersensitivity reactions (may be severe; discontinue if occur).
To report infections that may have been transmitted by Cinryze, call CinryzeSolutions at (877) 945-1000.
Endocrinology Advisor Articles
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Link Between Gestational Diabetes and Risk for CVD and Diabetes in Hispanic/Latina Population
- Clinical Characteristics Altering Risks and Benefits of Sulfonylureas and Thiazolidinedione Therapy in T2D
- 6 Factors Related to Inclusion in Health Care Workplace Identified
- Weight Gain After Quitting Smoking May Increase Risk for T2D